XOMA Royalty Corp
About XOMA Royalty Corp
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $10.3M
- Net income
- $31.7M
- Total assets
- $272.7M
- Market cap
- $527.9M
- Operating margin
- 21.8%
- Net margin
- 60.8%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $52.1M
- Operating expenses
- $40.8M
- Operating income
- $11.4M
- Income tax
- $103.0K
- Net income
- $31.7M
- EPS (basic)
- $1.53
- EPS (diluted)
- $1.46
Balance sheet
- Total assets
- $272.7M
- Current assets
- $117.3M
- Total liabilities
- $168.7M
- Current liabilities
- $34.8M
- Shareholders’ equity
- $83.9M
Cash flow
- Operating cash flow
- $2.9M
- Investing cash flow
- $50.9M
- Financing cash flow
- -$26.5M
- Net cash flow
- $27.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $527.9M
- P/E ratio
- 28.6
- EPS (diluted)
- $1.46
- Shares outstanding
- 12.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 6, 1986
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $31.7M in FY2025.
- Revenue grew 37% from FY2021 to FY2025.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 28.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review XOMA Royalty Corp.
Write a review
News about XOMA Royalty Corp
News & sentiment via Polygon.io
